Agenus (Agenus) Interest Expense : $-97.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Agenus Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Agenus's interest expense for the three months ended in Dec. 2023 was $ -44.2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-97.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Agenus's Operating Income for the three months ended in Dec. 2023 was $ -4.4 Mil. Agenus's Interest Expense for the three months ended in Dec. 2023 was $ -44.2 Mil. Agenus did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Agenus Interest Expense Historical Data

The historical data trend for Agenus's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Interest Expense Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-41.45

-61.08

-65.72

-61.86

-97.93

Agenus Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-17.33	-16.59	-18.52	-18.63	-44.18

Agenus Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.9 Mil.

Agenus (NAS:AGEN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Agenus's Interest Expense for the three months ended in Dec. 2023 was $-44.2 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-4.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $75.3 Mil.

Agenus's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Agenus did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Agenus (Agenus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AJ81:Germany AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Executives

Ulf Wiinberg	director
Steven J O'day	officer: Chief Medical Officer	2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen	officer: Chairman & CEO	3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin	officer: VP Finance	3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss	officer: Chief Legal Officer	139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp	10 percent owner	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan	officer: Chief Technology Officer	3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis	officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns	officer: V.P. and General Counsel	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell	officer: Chief Operating Officer	3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis	director	FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan	director	ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010